FeesSafety
Pluang+

Iovance's revenue jumps 77% but lung cancer trial results drag stock down 48%

Market News
16 Nov 2026, 10:22 WIB
Seeking Alpha
View Source
Bullish
Iovance's revenue jumps 77% but lung cancer trial results drag stock down 48%

Iovance Biotherapeutics reported a strong quarter with Amtagvi revenue up 77% to $101.6 million and nearly halted cash burn at -$4.47 million. However, disappointing lung cancer trial results caused the stock to drop 47.6% since October 28, as the response rate was below expectations. The company's fair value is estimated between $8.86 and $13.32 per share, higher than the current price of $7.76, suggesting a buying opportunity if fourth-quarter revenue exceeds $122.79 million. Investors will watch upcoming revenue figures closely to confirm the stock's outlook.

Iovance Biotherapeutics shares are trading at $7.72 on Pluang as of Nov 16, 2026 15:41 WIB, slightly down 0.52% for the day. The stock's market cap stands at $3.59 billion, reflecting investor interest despite recent trial setbacks. Trading volume is active with over 11.6 million shares changing hands, indicating ongoing market attention.

More News (IOVA)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App